The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82.
Freshpet, Inc.
FRPT · Nasdaq · USD · Market cap $3.4B · 1,288 employees
Freshpet, Inc., together with its subsidiaries, manufactures, distributes, and markets natural fresh meals and treats for dogs and cats in the United States, Canada, and Europe.
PASS · Titan Ethical · score 70.0Price as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price67.51 USD at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.60)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $58.38 to $67.13, base estimate $58.38 (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.60, read 2026-11-15
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Freshpet, Inc. holds its Distribution at $67.51. Consolidating, no directional conviction, held for 3 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 3 days |
| Price at the screen | $67.51 |
| Valuation | 18.81 trailing · 36.56 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.71 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 27.84% | Below 33% | Interest-bearing debt is just 27.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 1.88% | Below 33% | Cash held in interest-bearing accounts and securities is 1.9% of assets, under the one-third limit. | Pass |
| Receivables | 19.22% | Below 49% | Money owed to the company is 19.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.84% | Below 5% | Only 0.8% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Freshpet, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when FRPT's ethical verdict changes
Today FRPT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $58.38 fair value estimate, 15.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 15.6% above the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +19% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $58.38, with a range of $58.38 to $67.13, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPremium pet food priced beyond its value
Picture a dog owner paying top dollar for fresh meals that feel like human-grade cooking. Freshpet delivers solid 13% revenue growth and 18% profit margins with 17% returns on equity, yet the shares trade at 31.4 times forward earnings, just above our fair value with a negative margin of safety. The market already prices in the growth story, leaving no clear entry point despite the ethical screen pass.
We pass because the numbers do not stack up for new capital. Consensus targets sit near 80 from sixteen analysts, but that optimism sits against a valuation that already bakes in continued expansion without room for error. Unknown competitive moat adds another layer of uncertainty in a category where big food groups can copy recipes quickly.
High multiples on modest growth carry real downside if consumer spending on premium pet products slows. Defensive label offers some cushion, yet paying above fair value still leaves investors exposed to any miss on the growth path. Analysis, not advice.
| Forward P/E | 36.6xexpensive even after accounting for its growth |
| Trailing P/E | 18.8xreasonably valued |
| EPS, trailing | 3.79 |
| EPS, forward | 1.95 |
| Revenue growth | +15.5%steady growth |
| Profit margin | 17.3%healthy profit margins |
| Return on equity | 17.6%a solid return on shareholder capital |
| FCF yield | 0.56% |
| Debt to equity | 0.40minimal debt: a conservative balance sheet |
| Current ratio | 6.05comfortably covers its short-term bills |
| Beta | 1.71much more volatile than the market |
| Short interest, float | 0.19% |
| 52-week range | 46.45 - 86.00 |
| Market cap | $3.4B |
| Employees | 1,288 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeFRPT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $82.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Freshpet (FRPT) Lifted Guidance And Finished Its Buyback, Is It Still Below Fair Value? Yahoo Finance · 8d ago
- Freshpet, Inc. to Participate in Upcoming Investor Conferences Yahoo Finance · 11d ago
- Freshpet Inc (FRPT) Q3 2026 Earnings Call Highlights: Record Gross Margin, Raised Guidance and ... Yahoo Finance · 11d ago
- Freshpet: 3 Key Takeaways for Long-Term Investors Yahoo Finance · 11d ago
- Freshpet, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 11d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $49.64 | +2.3% | · | $1,023 | +2.3% |
| 2 months | $64.80 | -21.6% | · | $784 | -21.6% |
| 3 months | $78.04 | -34.9% | · | $651 | -34.9% |
| 6 months | $62.89 | -19.2% | · | $808 | -19.2% |
| 1 year | $78.89 | -35.6% | · | $644 | -35.6% |
| 2 years | $129.93 | -60.9% | · | $391 | -60.9% |
| 3 years | $66.07 | -23.1% | · | $769 | -23.1% |
| 5 years | $167.74 | -69.7% | · | $303 | -69.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever FRPT does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.